AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

AN2 Therapeutics granted inducement equity awards to Cameron Trenor, M.D., its newly-appointed Chief Medical Officer, under NASDAQ Listing Rule 5635(c)(4). The awards consist of options to purchase 233,333 shares at a $5.36 exercise price — equal to the closing price on the September 15, 2026 grant date — plus RSUs covering 116,667 shares, for roughly 350,000 total shares. The option carries a 10-year term and vests over four years with a 25% cliff on the one-year hire anniversary of August 24, 2026; 10,400 RSUs vest January 1, 2027 with the remainder in roughly three equal annual installments beginning January 1, 2028.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.